While IL-1 targeting therapies represent the gold-standard of treatment in sJIA and are also applied first-line [46], in AOSD, they are frequently introduced later in the disease course, and guidelines still recommend the use of drugs such as methotrexate or calcineurin inhibitors (i.e., cyclosporin) [47]. The gene discussed is IL1B; the disease is adult-onset Still disease.